Clarivate Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLVT research report →
Range $2 – $2.25
Price Chart
About the company
Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio.
- CEO
- Matitiahu Shem Tov
- IPO
- 2018
- Employees
- 12,000
- HQ
- London, GL, GB
Get TickerSpark's AI analysis on CLVT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.29B
- P/E
- -3.37
- Fwd P/E
- 2.66
- PEG
- 0.02
- P/S
- 0.58
- P/B
- 0.29
- EV/EBITDA
- 8.29
- Div Yield
- 0.00%
- Gross Margin
- 68.24%
- Op Margin
- -3.90%
- Net Margin
- -17.02%
- ROE
- -8.27%
- ROIC
- -0.98%
Latest fiscal year · YoY change
- Revenue
- $2.46B-4.0%
- Gross Profit
- $1.62B-3.9%
- Op Income
- $71.50M
- Net Income
- $-201,100,000+68.4%
- EPS
- $-0.30+68.7%
- OCF Growth
- -2.8%
- FCF Growth
- +2.2%
- 52W High
- $3.87
- 52W Low
- $1.42
- 50D MA
- $1.87
- 200D MA
- $2.19
- Beta
- 1.39
- RSI (14)
- 47
- Avg Volume
- 4.11M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Clarivate said Q3 marked a key transformation milestone, with improving recurring growth, stronger margins, and a focused strategy after selling Life Sciences & Healthcare ahead of schedule.· November 3, 2026
- Completed the Life Sciences & Healthcare sale ahead of schedule, leaving Clarivate focused on Academia & Government and IP.
- Organic ACV grew 1.8%, recurring organic revenue improved to 1.3%, and IP ACV returned to positive growth for the first time in over 3 years.
- Q3 revenue from continuing operations was $482 million; adjusted diluted EPS was $0.21; operating cash flow was $166 million.
- Management raised full-year expectations for recurring organic revenue to 1% to 1.5%, adjusted EBITDA to $865 million to $885 million, and free cash flow to $320 million to $340 million.
- Management highlighted AI-led products and pipelines, including more than 80 in-market AI capabilities, Web of Science Research Intelligence, and IPOne.
Q3 revenue from continuing operations was $482 million, and year-to-date revenue was nearly $1.5 billion. Adjusted diluted EPS in Q3 was $0.21, up $0.03 year over year, and year-to-date adjusted diluted EPS was $0.59, up 20%. Operating cash flow was $166 million in the quarter, and free cash flow was $110 million. Management said Q3 recurring organic revenue growth was 1.3% and organic ACV growth was 1.8%, while adjusted EBITDA margin expanded over 300 basis points versus the prior year. For the full year, Clarivate now expects revenue of $1.965 billion to $1.985 billion, adjusted EBITDA of $865 million to $885 million, adjusted EPS of about $0.75, and free cash flow of $320 million to $340 million. Management also guided to organic ACV growth of 1.75% to 2.25% and recurring organic revenue growth of 1% to 1.5% for the full year, with Q4 recurring organic revenue growth expected to exceed 2%.
Matti Shem Tov framed Q3 as proof that Clarivate’s transformation is working, emphasizing a more focused, higher-quality recurring business after the LS&H sale. He highlighted improving commercial traction in both A&G and IP, with AI positioned as a key differentiator through products like Web of Science Research Intelligence and IPOne. His tone was confident and execution-focused, repeatedly pointing to a clearer path toward stronger organic growth, higher free cash flow, and lower leverage.
Michael Easton said continuing-operations revenue was $482 million in Q3, adjusted diluted EPS was $0.21, operating cash flow was $166 million, and free cash flow was $110 million. He said margin expansion came from recurring revenue growth, strategic disposals, and disciplined cost management, and noted year-to-date debt reduction of $293 million after repurchasing another $75 million of notes due in 2028 at about a 2% discount. He also updated full-year guidance to $1.965 billion to $1.985 billion of revenue, $865 million to $885 million of adjusted EBITDA, and $320 million to $340 million of free cash flow, citing about $30 million of transaction costs and lower fourth-quarter free cash flow after the divestiture.
Analysts focused on what is driving the ACV improvement and how it will translate into revenue, especially in IP where ACV turned positive but segment organic revenue was still down 0.4%. Management said pricing has been a primary driver, with pricing running consistently and strongly and volumes improving, and reiterated a goal of exiting the year at about 2% ACV growth and then improving further in 2027. On IP, management said the business is more stabilized, has a tighter sales organization, and should benefit from IPOne both for new ACV and retention. In a separate question, management said it plans to buy back 2028 and 2029 notes in the fourth quarter at similar discounts to prior buybacks, balancing the two maturities based on timing and capital allocation priorities.
The call suggested Clarivate is emerging as a more focused recurring-revenue business after the LS&H sale, with improving KPI momentum and management saying the strategy is working. Bullish points included 1.8% ACV growth, positive IP ACV growth, expanding margins, and an AI product pipeline that management believes can create new revenue streams and improve retention.
The company still showed only modest organic growth, with total organic revenue up just 0.4% in Q3 and recurring organic revenue at 1.3%. Management also acknowledged ongoing revenue headwinds from the A&G books wind-down and smaller low-margin transactional product exits, plus foreign-exchange pressure and higher taxes/working capital that weighed on cash flow.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 52.3%
- Shares Outstanding
- 639.90M
- Float Shares
- 334.78M
of shares held by institutions
249 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CLVT, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Leonard Green & Partners, L.P. | 116.67M | 0 |
| Exor N.V. | 67.29M | 0 |
| Clarkston Capital Partners, LLC | 42.60M | ▼ 3.13M |
| Blackrock, Inc. | 31.61M | ▲ 459.35K |
| Partners Group Holding AG | 25.58M | 0 |
| Fil Ltd | 25.27M | 0 |
| American Century Companies Inc | 18.57M | ▲ 4.30M |
| Citadel Advisors LLC | 14.63M | ▼ 3.06M |
| Invenomic Capital Management LP | 14.26M | ▲ 951.24K |
| Dimensional Fund Advisors LP | 13.89M | ▼ 5.18M |
| Bw Gestao De Investimentos Ltda. | 12.67M | ▲ 2.63M |
| Atairos Group, Inc. | 12.26M | 0 |
Held by 221 ETFs
Biggest fund positions in CLVT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Veinstein Bar | sell | 254,558 |
| Oct 6, 26 | Levy Henry | other | 263,576 |
| Sep 30, 26 | Cornick Kenneth L. | other | 17,215 |
| Sep 30, 26 | Cornick Kenneth L. | other | 3,444 |
| Sep 30, 26 | Bomba Jane L Okun | other | 17,215 |
| Sep 30, 26 | Bomba Jane L Okun | other | 181 |
| Sep 30, 26 | Snyder Andrew Miles | other | 30,688 |
| Sep 30, 26 | Snyder Andrew Miles | other | 1,012 |
| Aug 15, 26 | Lisowski Matthew J. | other | 67,357 |
| Aug 15, 26 | Easton Michael M | other | 194,300 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLVT coverage
Recent articles, reports, and earnings notes.
No research on CLVT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLVT report →Clarivate Reveals Highly Cited Researchers 2026 List
prnewswire.com · Nov 18
Clarivate Announces Final Results of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
prnewswire.com · Nov 12
Clarivate to Present at the RBC Capital Markets Global Technology, Internet, Media and Telecommunications Conference on November 18
prnewswire.com · Nov 11
Clarivate's IPOne Connects Trusted Patent, Trademark and Litigation Intelligence to Claude
prnewswire.com · Nov 11
Clarivate Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
prnewswire.com · Nov 10
Clarivate Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
prnewswire.com · Nov 10
Clarivate PLC: Return Of Organic Growth Confirms Speculative Appeal
seekingalpha.com · Nov 7
Clarivate Commences Offers to Purchase for Cash Certain of its Outstanding Debt Securities
prnewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.